Juan M. Saavedra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Juan M. Saavedra has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Abdel Elkahloun
Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
1 shared publication Abdel G. Elkahloun
Microarray Core, Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, 50 South Dr, MSC 4435, Bethesda, MD, 20892-4435, USA
1 shared publication- Abdel G. Elkahloun
National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA
1 shared publication - Alexandra Perez
Nova Southeastern University Barry and Judy Silverman College of Pharmacy, Fort Lauderdale, FL
1 shared publication Daniela Jezova
1 shared publicationErin Wenzel
Laboratory of Neuroprotection, Department of Pharmacology and Physiology, Georgetown University Medical Center, SE402 Med/Dent, 3900 Reservoir Road, Washington, DC, 20057, USA
1 shared publication
Latest Publications
- 15 October 2021
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 42 (2) , 311-313
Introduction to the Special Issue “The Brain-Gut Axis”
This special Issue presents comprehensive and state-of-the-art advances in supporting the crucial role of the bidirectional interactions between the Brain-
- 15 October 2021
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 42 (2) , 311-313
Introduction to the Special Issue “The Brain-Gut Axis”
This special Issue presents comprehensive and state-of-the-art advances in supporting the crucial role of the bidirectional interactions between the Brain-
- 1 May 2021
- Published by American Physiological Society in Physiology
- Vol. 36 (3) , 160-173
Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore
Beyond blood pressure control, angiotensin receptor blockers reduce common injury mechanisms, decreasing excessive inflammation and protecting endothelial and mitochondrial function, insulin sensitivity, the coagulation cascade, immune responses, cerebrovascular flow, and cognition, properties useful to treat inflammatory, age-related, neurodegenerative, and metabolic disorders of many organs including brain and lung.
- 1 May 2021
- Published by American Physiological Society in Physiology
- Vol. 36 (3) , 160-173
Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore
Beyond blood pressure control, angiotensin receptor blockers reduce common injury mechanisms, decreasing excessive inflammation and protecting endothelial and mitochondrial function, insulin sensitivity, the coagulation cascade, immune responses, cerebrovascular flow, and cognition, properties useful to treat inflammatory, age-related, neurodegenerative, and metabolic disorders of many organs including brain and lung.
- Open Access
- 1 November 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 131, 110653
Candesartan could ameliorate the COVID-19 cytokine storm
- 1 November 2020
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 131, 110653
Open AccessCandesartan could ameliorate the COVID-19 cytokine storm
- 1 September 2020
- Published by Elsevier in Pharmacological Research
- Vol. 159, 104958
Angiotensin receptor blockers for the treatment of COVID-19 and its comorbidities
- 1 September 2020
- Published by Elsevier in Pharmacological Research
- Vol. 159, 104958
Angiotensin receptor blockers for the treatment of COVID-19 and its comorbidities
- Open Access
Trends in Angiotensin Receptor Blocker Use Among those at Risk for COVID-19 Morbidity and Mortality in the United States
Importance: Assessment of the use of angiotensin receptor blockers (ARBs) in the United States provides insight into prescribing practices, and may inform guidelines, policy measures and research during the COVID-19 pandemic. Objective: To evaluate trends in ARB use among adults in the United States who have preexisting conditions and sociodemographic risk factors that put them at a higher risk of SARS-CoV-2 infection and COVID-19-related complications and mortality. Design, setting and participants: This study uses the nationally representative cross-sectional data from the 2005-2018 National Health and Nutrition Examination Survey (NHANES). Participants included 39,749 non-institutionalized U.S. civilian adults who were 20 years and older and those with the most common preexisting conditions and risk factors reported among patients with COVID-19. Main outcomes and measures: Use of ARBs in the prior 30 days from survey interview. Results: ARB use ranged from 7.4% [95% CI, 6.5%-8.4%] to 26.2% [95% CI, 19.4%-34.4%] among those with one or two metabolic, renal, respiratory, and/or cardiovascular diseases. Among individuals with the three most common preexisting conditions in patients with COVID-19 including hypertension, diabetes and obesity, ARB use was higher among the elderly, females, non-Hispanic whites, and those with health insurance coverage. Conclusions and relevance: In this nationally representative survey, ARB use was found to be widespread, but unevenly distributed among individuals with conditions and sociodemographic risk factors that place them at a higher risk of COVID-19 morbidity and mortality. Key Points: Question: What is the prevalence of angiotensin receptor blocker (ARB) use among individuals at higher risk of COVID-19-related complications? Findings: In a cross-sectional study with data from 39,749 adult participants of the National Health and Nutrition Examination Survey, ARB use ranged between 7.4% and 26.2% among those with one or two respiratory, metabolic, renal and/or cardiovascular diseases. Significant disparities in ARB use were found in participants with preexisting conditions and sociodemographic factors that place them at a higher risk of COVID-19 morbidity and mortality. Meaning: ARB use is widespread and disproportionate in the United States among people at higher risk of COVID-19 complications.
Open AccessTrends in Angiotensin Receptor Blocker Use Among those at Risk for COVID-19 Morbidity and Mortality in the United States
Importance: Assessment of the use of angiotensin receptor blockers (ARBs) in the United States provides insight into prescribing practices, and may inform guidelines, policy measures and research during the COVID-19 pandemic. Objective: To evaluate trends in ARB use among adults in the United States who have preexisting conditions and sociodemographic risk factors that put them at a higher risk of SARS-CoV-2 infection and COVID-19-related complications and mortality. Design, setting and participants: This study uses the nationally representative cross-sectional data from the 2005-2018 National Health and Nutrition Examination Survey (NHANES). Participants included 39,749 non-institutionalized U.S. civilian adults who were 20 years and older and those with the most common preexisting conditions and risk factors reported among patients with COVID-19. Main outcomes and measures: Use of ARBs in the prior 30 days from survey interview. Results: ARB use ranged from 7.4% [95% CI, 6.5%-8.4%] to 26.2% [95% CI, 19.4%-34.4%] among those with one or two metabolic, renal, respiratory, and/or cardiovascular diseases. Among individuals with the three most common preexisting conditions in patients with COVID-19 including hypertension, diabetes and obesity, ARB use was higher among the elderly, females, non-Hispanic whites, and those with health insurance coverage. Conclusions and relevance: In this nationally representative survey, ARB use was found to be widespread, but unevenly distributed among individuals with conditions and sociodemographic risk factors that place them at a higher risk of COVID-19 morbidity and mortality. Key Points: Question: What is the prevalence of angiotensin receptor blocker (ARB) use among individuals at higher risk of COVID-19-related complications? Findings: In a cross-sectional study with data from 39,749 adult participants of the National Health and Nutrition Examination Survey, ARB use ranged between 7.4% and 26.2% among those with one or two respiratory, metabolic, renal and/or cardiovascular diseases. Significant disparities in ARB use were found in participants with preexisting conditions and sociodemographic factors that place them at a higher risk of COVID-19 morbidity and mortality. Meaning: ARB use is widespread and disproportionate in the United States among people at higher risk of COVID-19 complications.
- 1 June 2020
- Published by Elsevier in Pharmacological Research
- Vol. 156, 104832
Angiotensin receptor blockers and COVID-19
- 1 June 2020
- Published by Elsevier in Pharmacological Research
- Vol. 156, 104832
Angiotensin receptor blockers and COVID-19
- Open Access
- 8 May 2020
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 40 (5) , 667-674
COVID-19, Angiotensin Receptor Blockers, and the Brain
- 8 May 2020
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 40 (5) , 667-674
Open AccessCOVID-19, Angiotensin Receptor Blockers, and the Brain
- 31 January 2020
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 40 (2) , 189-190
Trace Amines and Trace Amine-Associated Receptors: A New Frontier in Cell Signaling
Trace amines, including β-phenylethylamine, p-octopamine, p-tyramine, and tryptamine, are produced in high levels in invertebrates where they play major roles in homeostasis regulation in a manner similar to that of adrenergic systems in mammals (Rutigliano et al. in Front Pharmacol 8:987, 2017 ; Gainetdinov et al. in Pharmacol Rev 70(3):549–620, 2018 ; Nagaya et al. in Neurosci Lett 329(3):324–328, 2002 ). In mammals, however, their levels are very low, initially prompting these molecules to be termed “trace” or “minor” amines in mammals with only a secondary role in the regulation of more abundant biogenic amines including catecholamines and serotonin (Gainetdinov et al. in Pharmacol Rev 70(3):549–620, 2018 ). The more recent discovery of trace amine-associated receptors (TAARs) revealed major, previously unsuspected roles of the trace amines and has led to increasing interest within the scientific community. For example, TAARs have been proposed to modulate signaling through dopamine (Schwartz et al. in Expert Opin Ther Targets 22(6):513–526, 2018 ). Furthermore, these receptors are implicated in both numerous physiological functions including regulation of sleep, olfaction, metabolism, and immunity as well in disease (e.g., substance abuse, neuropsychiatric disorders) (Gainetdinov et al. in Pharmacol Rev 70(3):549–620, 2018 ; Rutigliano et al. in Front Pharmacol 8:987, 2017 ). Consequently, trace amine and TAAR research is rapidly growing and is of great translational relevance. In this Special Issue, leaders in trace amine and TAAR research offer both reviews and original research papers that cover a wide range of topics from involvement of TAAR signaling in metabolic regulation and neurophysiology to implications of this signaling in neuropsychiatric diseases including substance abuse and schizophrenia. While a diverse range of topics is covered by these works, the common theme running through all of them is the increasing awareness that trace amine and TAAR signaling represent novel signaling mechanisms in the brain and periphery. These topics are both highly timely and of considerable importance not only for those working in the field but also for the neuroscience community at large.
- 31 January 2020
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 40 (2) , 189-190
Trace Amines and Trace Amine-Associated Receptors: A New Frontier in Cell Signaling
Trace amines, including β-phenylethylamine, p-octopamine, p-tyramine, and tryptamine, are produced in high levels in invertebrates where they play major roles in homeostasis regulation in a manner similar to that of adrenergic systems in mammals (Rutigliano et al. in Front Pharmacol 8:987, 2017 ; Gainetdinov et al. in Pharmacol Rev 70(3):549–620, 2018 ; Nagaya et al. in Neurosci Lett 329(3):324–328, 2002 ). In mammals, however, their levels are very low, initially prompting these molecules to be termed “trace” or “minor” amines in mammals with only a secondary role in the regulation of more abundant biogenic amines including catecholamines and serotonin (Gainetdinov et al. in Pharmacol Rev 70(3):549–620, 2018 ). The more recent discovery of trace amine-associated receptors (TAARs) revealed major, previously unsuspected roles of the trace amines and has led to increasing interest within the scientific community. For example, TAARs have been proposed to modulate signaling through dopamine (Schwartz et al. in Expert Opin Ther Targets 22(6):513–526, 2018 ). Furthermore, these receptors are implicated in both numerous physiological functions including regulation of sleep, olfaction, metabolism, and immunity as well in disease (e.g., substance abuse, neuropsychiatric disorders) (Gainetdinov et al. in Pharmacol Rev 70(3):549–620, 2018 ; Rutigliano et al. in Front Pharmacol 8:987, 2017 ). Consequently, trace amine and TAAR research is rapidly growing and is of great translational relevance. In this Special Issue, leaders in trace amine and TAAR research offer both reviews and original research papers that cover a wide range of topics from involvement of TAAR signaling in metabolic regulation and neurophysiology to implications of this signaling in neuropsychiatric diseases including substance abuse and schizophrenia. While a diverse range of topics is covered by these works, the common theme running through all of them is the increasing awareness that trace amine and TAAR signaling represent novel signaling mechanisms in the brain and periphery. These topics are both highly timely and of considerable importance not only for those working in the field but also for the neuroscience community at large.
- 7 December 2019
- Published by Springer Nature in Molecular Neurobiology
- Vol. 57 (3) , 1656-1673
Candesartan Neuroprotection in Rat Primary Neurons Negatively Correlates with Aging and Senescence: a Transcriptomic Analysis
Preclinical experiments and clinical trials demonstrated that angiotensin II AT1 receptor overactivity associates with aging and cellular senescence and that AT1 receptor blockers (ARBs) protect from age-related brain disorders. In a primary neuronal culture submitted to glutamate excitotoxicity, gene set enrichment analysis (GSEA) revealed expression of several hundred genes altered by glutamate and normalized by candesartan correlated with changes in expression in Alzheimer’s patient’s hippocampus. To further establish whether our data correlated with gene expression alterations associated with aging and senescence, we compared our global transcriptional data with additional published datasets, including alterations in gene expression in the neocortex and cerebellum of old mice, human frontal cortex after age of 40, gene alterations in the Werner syndrome, rodent caloric restriction, Ras and oncogene-induced senescence in fibroblasts, and to tissues besides the brain such as the muscle and kidney. The most significant and enriched pathways associated with aging and senescence were positively correlated with alterations in gene expression in glutamate-injured neurons and, conversely, negatively correlated when the injured neurons were treated with candesartan. Our results involve multiple genes and pathways, including CAV1, CCND1, CDKN1A, CHEK1, ICAM1, IL-1B, IL-6, MAPK14, PTGS2, SERPINE1, and TP53, encoding proteins associated with aging and senescence hallmarks, such as inflammation, oxidative stress, cell cycle and mitochondrial function alterations, insulin resistance, genomic instability including telomere shortening and DNA damage, and the senescent-associated secretory phenotype. Our results demonstrate that AT1 receptor blockade ameliorates central mechanisms of aging and senescence. Using ARBs for prevention and treatment of age-related disorders has important translational value.
- 7 December 2019
- Published by Springer Nature in Molecular Neurobiology
- Vol. 57 (3) , 1656-1673
Candesartan Neuroprotection in Rat Primary Neurons Negatively Correlates with Aging and Senescence: a Transcriptomic Analysis
Preclinical experiments and clinical trials demonstrated that angiotensin II AT1 receptor overactivity associates with aging and cellular senescence and that AT1 receptor blockers (ARBs) protect from age-related brain disorders. In a primary neuronal culture submitted to glutamate excitotoxicity, gene set enrichment analysis (GSEA) revealed expression of several hundred genes altered by glutamate and normalized by candesartan correlated with changes in expression in Alzheimer’s patient’s hippocampus. To further establish whether our data correlated with gene expression alterations associated with aging and senescence, we compared our global transcriptional data with additional published datasets, including alterations in gene expression in the neocortex and cerebellum of old mice, human frontal cortex after age of 40, gene alterations in the Werner syndrome, rodent caloric restriction, Ras and oncogene-induced senescence in fibroblasts, and to tissues besides the brain such as the muscle and kidney. The most significant and enriched pathways associated with aging and senescence were positively correlated with alterations in gene expression in glutamate-injured neurons and, conversely, negatively correlated when the injured neurons were treated with candesartan. Our results involve multiple genes and pathways, including CAV1, CCND1, CDKN1A, CHEK1, ICAM1, IL-1B, IL-6, MAPK14, PTGS2, SERPINE1, and TP53, encoding proteins associated with aging and senescence hallmarks, such as inflammation, oxidative stress, cell cycle and mitochondrial function alterations, insulin resistance, genomic instability including telomere shortening and DNA damage, and the senescent-associated secretory phenotype. Our results demonstrate that AT1 receptor blockade ameliorates central mechanisms of aging and senescence. Using ARBs for prevention and treatment of age-related disorders has important translational value.
- 23 May 2019
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 39 (7) , 899-900
In Memoriam: Horst Grobecker (1934–2019)
- 23 May 2019
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 39 (7) , 899-900
In Memoriam: Horst Grobecker (1934–2019)